Skip to main content
CRISM Therapeutics Corporation logo

CRISM Therapeutics Corporation — Investor Relations & Filings

Ticker · CRTX ISIN · VGG042401262 LEI · 213800XFW6MKVCHHPW88 US Manufacturing
Open in API
Filings indexed 447 across all filing types
Latest filing 2026-05-28 Capital/Financing Update
Country VG Virgin Islands (British)
Listing US CRTX

About CRISM Therapeutics Corporation

https://www.crismtherapeutics.com/

CRISM Therapeutics Corporation is a pharmaceutical company focused on developing advanced drug delivery technologies. Its flagship product, ChemoSeed®, is an implantable, biodegradable technology designed for the sustained and localized delivery of chemotherapy drugs directly into solid tumors. The primary objective of this approach is to enhance the efficacy of cancer treatments by concentrating therapeutic agents at the tumor site, thereby minimizing systemic toxicity and associated side effects. The company's technology aims to improve the clinical performance of cancer therapies and the bioavailability of poorly soluble compounds, with a mission to provide more effective and better-tolerated treatments to improve patient quality of life.

Recent filings

Filing Released Lang Actions
Result of Retail Offer
Capital/Financing Update Classification · 85% confidence The document is an RNS announcement detailing the successful completion and closing of a retail offer—an oversubscribed share issuance to raise equity finance. It provides fundraising details, number of shares, and conditions for the issuance. This is a capital-raising update rather than a full report, AGM materials, or regulatory filing of another type. Thus it best fits the Capital/Financing Update category.
2026-05-28 English
Notice of General Meeting
Regulatory Filings Classification · 85% confidence The document is a short RNS announcement (under 5,000 characters) on the London Stock Exchange, notifying investors of a forthcoming General Meeting and stating that the full Notice of General Meeting will be posted on the company website. It contains no substantive financial data, proxy materials, or detailed governance content itself—only an announcement. Therefore it falls under the general regulatory announcements (RNS) category.
2026-05-27 English
Retail Offer to raise up to £100,000
Capital/Financing Update Classification · 90% confidence The document is an RNS announcement by CRISM Therapeutics Corporation outlining a Retail Offer and Placing of new ordinary shares to raise up to £100,000. It details the issue price, timetable, conditions of the Retail Offer, admission to trading, and other capital-raising mechanics. There are no financial statements or results being reported, nor is it an earnings release, governance update, or AGM material. This is a financing/capital raising update, so it falls under the Capital/Financing Update category.
2026-05-26 English
Placing of £2.5 million
Capital/Financing Update Classification · 92% confidence The document is an RNS announcement detailing a fundraising via a placing of 25 million new ordinary shares for £2.5 million, including terms, warrant issue, timetable, and admission details. It is a capital raising/financing update rather than an interim report, dividend notice, or shareholding notification. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-26 English
Positive Preclinical Data for Docetaxel ChemoSeed
Regulatory Filings Classification · 85% confidence The document is an RNS press release announcing positive preclinical data for CRISM Therapeutics’ Docetaxel-ChemoSeed technology. It is not a financial report (e.g., 10-K, interim report, earnings release), not governance or board changes, not dividend or share transaction related, nor an investor presentation or proxy statement. It is a generic regulatory news announcement via the London Stock Exchange’s RNS service, so it falls under the fallback Regulatory Filings category.
2026-04-21 English
Board Changes
Board/Management Information Classification · 92% confidence The document is an RNS announcement on AIM detailing the resignation of a Non-Executive Chair and interim board arrangements. It specifically covers changes to the Board of Directors, which matches the Board/Management Information category. Thus, it is classified as MANG.
2026-04-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.